AI Gastroenterology Market
Every Market-Reports.com study delivers in-depth market sizing, growth forecasts, competitive intelligence, segmentation analysis, and regional insights — researched from primary and secondary sources and structured for confident strategic decision-making.
Market Snapshot
2025 Market Size
US$ 1.1 billion
Estimated Base Value
2035 Forecast
US$ 8.6 billion
Projected Market Value
CAGR 2026–2035
22.8%
Compound Annual Growth
Largest Segment
AI-powered Diagnostic Platforms
Fastest Growing Segment
AI for Disease Surveillance & Patient Monitoring
Leading Region
Asia Pacific
Fastest Growing Region
Emerging Areas
Top Country
United States
By Market Share
38.5% market share
Key Players
Iterative Health
Emerging Players
Freenome, Gutfeeling.ai
Market Definition & Overview
The AI Gastroenterology Market encompasses the development, deployment, and adoption of artificial intelligence technologies—including machine learning, deep learning, natural language processing, and computer vision—to enhance various aspects of gastrointestinal healthcare. This market covers AI-powered solutions aimed at improving the accuracy and efficiency of diagnosing GI disorders, optimizing treatment planning, predicting disease progression, and personalizing patient care. Key applications include AI-assisted endoscopic image analysis for polyp detection and characterization, predictive analytics for inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), automated pathology analysis of GI biopsies, and intelligent systems for drug discovery in gastroenterology, ultimately driving better patient outcomes and operational efficiencies within the healthcare system.
Scope
- Global market coverage across all major regions.
- Focus on commercially available AI software, platforms, and services for gastroenterology.
- Market analysis spans the period from 2023 to 2030.
Inclusions
- AI-assisted diagnostic tools for endoscopy (colonoscopy, gastroscopy) to detect polyps and lesions.
- Predictive analytics and risk stratification models for inflammatory bowel disease (IBD) and other chronic GI conditions.
- AI algorithms for personalized treatment planning and drug efficacy prediction in gastroenterology.
- Machine learning applications for pathology image analysis in gastrointestinal cancers.
- Natural Language Processing (NLP) tools for analyzing clinical notes and patient data in GI.
- AI-powered platforms for remote monitoring and management of GI patients.
Exclusions
- General-purpose AI platforms not specifically adapted for gastroenterology applications.
- Traditional, non-AI medical devices and imaging equipment used in gastroenterology.
- AI applications in other medical specialties such as cardiology, oncology (outside GI), or neurology.
- Basic data analytics tools lacking advanced AI or machine learning capabilities.
- Pure academic research on AI in gastroenterology without commercialization intent.
Market Size Forecast
Executive Summary
• The AI Gastroenterology market is valued at $1.1 Bn in 2025 and is forecast to reach $8.6 Bn by 2035, reflecting a robust CAGR of 22.8% as demand accelerates across every major segment and region over the ten-year outlook.
• AI-powered Diagnostic Platforms leads the segment breakdown by current market share, underscoring where the bulk of near-term revenue and competitive activity within this market is concentrated today.
• Asia Pacific commands the largest regional share at 35.0%, while Emerging Areas is expanding the fastest at a 11.0% CAGR, signalling where future growth is shifting.
• United States remains the single largest country-level market at 38.5% of global share, anchoring overall demand within its home region throughout the forecast period.
• The AI gastroenterology market is rapidly consolidating, driven by strategic acquisitions from established medical device firms and tech giants aiming to integrate advanced diagnostic and therapeutic AI solutions, fundamentally reshaping the competitive landscape and innovation trajectory.
• Key growth catalysts include the demonstrable clinical efficacy of AI in enhancing diagnostic precision for conditions like colorectal cancer and IBD, alongside its role in streamlining procedural workflows, significantly improving patient outcomes and clinician efficiency globally.
• Increasing regulatory clarity for AI-powered diagnostics and therapeutic support tools is de-risking investments, attracting substantial venture capital into specialized AI firms and fostering critical partnerships necessary for broad market adoption and scale.
• While developed markets currently lead adoption due to advanced infrastructure and reimbursement frameworks, emerging economies present substantial long-term growth potential, particularly for cost-effective AI solutions addressing widespread gastrointestinal diseases.
• The evolution towards real-time AI integration within endoscopy platforms and personalized predictive analytics represents a pivotal technological shift, promising to transform preventive care strategies and precision medicine applications across all GI segments.
• Ensuring robust, diverse real-world data access and developing secure, interoperable AI platforms are paramount strategic imperatives, dictating future supply chain resilience and successful AI solution deployment across diverse clinical settings worldwide.
Key Market Takeaways
Critical findings and data points from this market research study.
Initial Market Valuation
The AI Gastroenterology Market was valued at an impressive $1.1 billion in the base year, indicating a robust foundation for future growth.
Substantial Future Growth
The market is projected to achieve significant expansion, reaching $8.6 billion by the forecast year, demonstrating strong market potential.
High Growth Rate
This substantial market increase is driven by an impressive Compound Annual Growth Rate (CAGR) of 22.8% over the forecast period.
Diagnostic AI Leads
Diagnostic AI solutions are expected to emerge as a leading segment, spearheading market growth through enhanced accuracy and efficiency in disease detection.
Predictive Analytics Trend
A notable trend in the market is the increasing integration of predictive analytics, offering advanced insights for proactive disease management and personalized patient care.
Significant Market Expansion
The AI Gastroenterology Market is poised for nearly eightfold expansion from its base year value of $1.1 billion to $8.6 billion, signaling a dynamic and rapidly evolving sector.
Market Dynamics
Market Trends
- Growing AI integration in endoscopic imaging and analysis.
- Shift towards AI for predictive diagnosis of GI conditions.
- Increased adoption of AI in GI research and drug development.
- Focus on AI for personalized treatment plans in gastroenterology.
Growth Drivers
- High demand for accurate and early GI disease detection.
- Rising incidence of chronic gastrointestinal disorders globally.
- Technological advancements in AI and machine learning algorithms.
- Need to improve efficiency and reduce diagnostic errors.
Restraints
- Limited availability of large, high-quality gastroenterology datasets hinders AI training.
- High development and integration costs challenge widespread AI adoption in clinics.
- Regulatory complexities and slow approval processes impede market entry for AI solutions.
- Physician skepticism and trust issues concerning AI accuracy slow clinical acceptance.
Opportunities
- Developing AI solutions for remote monitoring of GI patients.
- Expanding AI applications in preventative gastroenterology.
- Creating AI platforms for precision medicine in GI treatments.
- Market penetration into underserved regions with high GI disease burden.
Market Dynamics Framework · 2026–2035
Need Custom Data for This Market?
Get tailored segmentation, deeper competitive intelligence, or region-specific deep dives from our analyst team.
Market Segmentation
| Segment | Sub-segments |
|---|---|
| By Type | AI-Powered Diagnostic PlatformsAI-Assisted Therapeutic Guidance SystemsAI for Disease Surveillance & Patient MonitoringAI in GI Drug Discovery & DevelopmentAI-Driven Clinical Workflow & Operational OptimizationAI for Predictive Analytics & Risk Stratification |
| By Technology | Machine LearningDeep LearningNatural Language ProcessingComputer VisionPredictive AnalyticsRobotics and AutomationRule-Based AI Systems |
| By Application | Colonoscopy & Endoscopy AssistanceInflammatory Bowel Disease ManagementGastroesophageal Reflux Disease & Esophageal DisordersHepatology & Liver DiseasesPancreatic & Biliary DisordersGastric & Small Bowel DisordersFunctional GI DisordersGastrointestinal Oncology |
| By End-User | HospitalsSpecialty Clinics & Gastroenterology PracticesAcademic & Research InstitutionsDiagnostic & Imaging CentersAmbulatory Surgical CentersPharmaceutical & Biotechnology CompaniesTelehealth & Remote Care Providers |
| By Deployment | Cloud-BasedOn-PremiseHybrid |
| By Component | SoftwareHardwareServices |
Regional Analysis
- North America leads the AI Gastroenterology market due to substantial healthcare IT investments, high adoption of advanced technologies, and a robust R&D ecosystem. The region's major AI solution providers and supportive regulatory frameworks further solidify its dominant position.
- Asia-Pacific is projected to be the fastest-growing region, fueled by its immense patient population, increasing healthcare IT infrastructure development, and rising awareness of AI's diagnostic benefits. Government support for digital health initiatives also significantly contributes to this rapid expansion.
- In Europe, there's a noteworthy trend towards integrating AI-powered GI solutions within established digital health ecosystems, emphasizing data privacy and interoperability. This focus ensures secure and efficient sharing of patient data across diverse healthcare providers for collaborative patient management.
Asia Pacific
8.5% CAGR
$0.4 Bn
35% share
- Driven by large patient populations, increasing healthcare expenditure, and rapid adoption of AI technologies in major economies like China, India, and Japan, making it the leading market.
North America
8.0% CAGR
$0.3 Bn
30% share
- Characterized by advanced healthcare infrastructure, high R&D investment, and strong adoption of cutting-edge AI solutions for diagnostics and treatment in gastroenterology.
Europe
7.8% CAGR
$0.2 Bn
20% share
- Benefits from robust healthcare systems and a focus on digital health, though market penetration can vary due to diverse regulatory landscapes and differing adoption rates across countries.
Latin America
9.5% CAGR
$0.1 Bn
7% share
- An emerging market with significant growth potential, fueled by increasing investment in healthcare infrastructure and a growing demand for advanced diagnostic and therapeutic tools, despite economic hurdles.
Middle East & Africa
9.8% CAGR
$0.1 Bn
6% share
- Shows promising growth, particularly in Gulf Cooperation Council (GCC) countries with high healthcare spending, while other parts of the region present both opportunities and challenges for AI adoption.
Emerging Areas
11.0% CAGR
$0.0 Bn
2% share
- Represents nascent markets with the smallest current share but the highest growth potential, as basic healthcare digitization efforts pave the way for future AI integration in underserved regions.
Country Analysis
United States and Brazil represent the largest country-level markets, with growth across the remaining countries shaped by local regulatory, infrastructure, and demand-side factors specific to each geography.
| # | Country | Market Size | CAGR | Key Driver |
|---|---|---|---|---|
| 1 | United States | $0.4 Bn | 18.5% | The U.S. leads in AI gastroenterology due to its vast healthcare expenditure, high adoption of advanced medical technologies, and significant prevalence of chronic GI diseases. Strong R&D and private investment further drive innovation and market growth. |
| 2 | Brazil | $0.0 Bn | 23.5% | As the largest economy in Latin America, Brazil's AI gastroenterology market is propelled by a large population, increasing digital health adoption, and efforts to improve access to advanced diagnostic and treatment technologies. |
| 3 | Germany | $0.1 Bn | 16.2% | Germany's advanced healthcare system and strong medical technology sector drive the adoption of AI in gastroenterology, focusing on high-precision diagnostics and personalized treatment approaches, backed by robust data protection standards. |
| 4 | China | $0.2 Bn | 20.5% | China's massive healthcare market, rapid technological advancement, and strong government backing for AI integration in medicine make it a dominant player in AI gastroenterology, especially in diagnostics and clinical decision support. |
| 5 | Saudi Arabia | $0.0 Bn | 24.0% | Driven by Vision 2030 and significant healthcare investments, Saudi Arabia is rapidly adopting AI in gastroenterology to modernize its healthcare system, improve diagnostic capabilities, and deliver advanced patient care. |
Countries Covered (22)
United States, Canada, Mexico, Brazil, Argentina, Rest of South America, Germany, United Kingdom, France, Spain, Italy, Rest of Europe, China, India, Japan, South Korea, Australia, Taiwan, Rest of Asia Pacific, Saudi Arabia, United Arab Emirates, Rest of Middle East & Africa
Competitive Landscape
| # | Company | Share | Key Strategy | Key Note | Key Developments | Key Products |
|---|---|---|---|---|---|---|
| 1 | Iterative Health | 5.7% | Leverage AI to improve colonoscopy quality and clinical trial recruitment efficiency in gastroenterology. | They are a leader in applying computer vision AI specifically for colonoscopy procedures. | Partnered with several major pharmaceutical companies to accelerate clinical trials for GI diseases. | SKOUTAI-powered polyp detectionPrecision Enrollment |
| 2 | Cosmo Pharmaceuticals | 5.4% | Develop and commercialize innovative medical devices and pharmaceuticals for gastrointestinal health through R&D and acquisitions. | They have a broad portfolio spanning medical devices, pharmaceuticals, and diagnostics in gastroenterology. | Received FDA approval for their methylene blue MMX oral solution for improved polyp detection. | EleviewLuminal imaging capsuleMethylene Blue MMX+1 |
| 3 | Wision A.I. | 5.1% | Focus on developing AI-assisted diagnostic tools to enhance the detection and characterization of lesions in endoscopic procedures. | One of the pioneering companies to achieve regulatory approvals for AI-powered colonoscopy systems in multiple markets. | Received CE Mark certification for its EndoScreener product in Europe, expanding its market reach. | EndoScreenerEndoScreener GIEndoScreener Colon |
| 4 | Vivante Health | 4.9% | Provide a comprehensive digital health solution for digestive diseases, integrating diet, lifestyle, and clinical support. | Offers a holistic, app-based digital therapeutic platform for managing chronic GI conditions, often provided through employers. | Partnered with numerous large employers and health plans to offer GIThrive as a covered benefit. | GIThrivePersonalized nutrition plansMental health support for GI conditions |
| 5 | Day Two | 4.6% | Utilize gut microbiome profiling and AI to provide personalized nutrition recommendations for metabolic and GI health. | Pioneered precision nutrition based on individual gut microbiome and blood sugar response to food. | Expanded its partnerships with health plans and employers across the US to offer its personalized nutrition solution. | Personalized nutrition programGut microbiome analysisPrediabetes management |
Market Positioning Map
Market share vs. growth outlook — bubble size is market share, bubble color is relative profitability
Companies Profiled (20)
Iterative Health, Cosmo Pharmaceuticals, Wision A.I., Vivante Health, Day Two, Viome Life Sciences, Mahana Therapeutics, Magentiq Eye, Salvo Health, MetaMe Health, Oshi Health, Medial EarlySign, Endolumina, KML Vision, Augmented Endoscopy, Pangea Biomed, Preserving Life Systems, Niron Kolon, EndoScan Technologies, Dieta Health
The global AI Gastroenterology market features a competitive landscape led by Iterative Health, Cosmo Pharmaceuticals, Wision A.I., Vivante Health, Day Two, and Viome Life Sciences, among other established and emerging players. Market participants continue to compete on product innovation, pricing strategy, geographic expansion, and strategic partnerships to strengthen their position in this evolving market.
* Market share estimates based on revenue analysis, primary interviews, and secondary research.
Company Profiles
Iterative Health
Cosmo Pharmaceuticals
Wision A.I.
Vivante Health
Day Two
Viome Life Sciences
Mahana Therapeutics
Magentiq Eye
Salvo Health
MetaMe Health
Oshi Health
Medial EarlySign
Endolumina
KML Vision
Augmented Endoscopy
Pangea Biomed
Preserving Life Systems
Niron Kolon
EndoScan Technologies
Dieta Health
* Classification reflects relative market share and maturity, derived from revenue analysis and public disclosures.
Ready to Make Data-Driven Decisions?
Purchase the full report or request a custom engagement. Get analyst support, scenario modelling, and real-time dashboard access.
Recent Market Developments
MedTech Giant Unveils Next-Gen AI for Colonoscopy
A leading medical technology company has launched its innovative AI-powered system designed to enhance polyp detection during colonoscopies, demonstrating significantly improved adenoma detection rates in clinical trials. This new platform aims to reduce missed lesions and improve early cancer detection.
Pharma Leader Partners with AI Firm for Personalized IBD Therapy
A major pharmaceutical company announced a strategic partnership with a specialized AI firm to leverage machine learning for predicting patient response to IBD treatments and developing personalized therapeutic strategies. The collaboration seeks to optimize drug efficacy and improve patient outcomes in inflammatory bowel disease.
Healthcare Tech Giant Acquires AI-Driven Digestive Health Platform
A prominent healthcare technology conglomerate has acquired a fast-growing startup known for its AI-powered digital platform offering personalized dietary recommendations and symptom tracking for various GI conditions. This acquisition expands the conglomerate's footprint in precision digestive health and patient-centric care.
AI GI Predictive Analytics Startup Secures $50M in Series B Funding
A startup focused on AI-driven predictive analytics for early detection and risk stratification of gastrointestinal diseases has successfully closed a $50 million Series B funding round. The investment will fuel product development, clinical validation, and global expansion of its platform, which helps clinicians proactively manage patient health.
Report Data Parameters
| Parameter | Value |
|---|---|
| Base Year | 2025 |
| Forecast Year | 2035 |
| Historical Period | 2019–2025 |
| Market Size (Base Year) | $1.1 Bn |
| Market Size (Forecast) | $8.6 Bn |
| CAGR | 22.8% |
| Forecast Period | 2026–2035 |
| Geography | Global |
| Countries Covered | 22 Countries |
| Segments Covered | 6 Segments, 34 Sub-segments |
| Companies Profiled | 20 Companies |
Report Value
Why Choose This Report
Complete Market Size
Accurate market sizing with historical data and a 10-year forecast across all scenarios.
Segment Analysis
Deep-dive segmentation by product, application, end-user, and technology verticals.
Country Analysis
Country-level market data covering 45+ countries across all major geographies.
Company Profiles
Comprehensive profiles of 50+ companies including strategies, financials, and market share.
Market Share
Detailed competitive market share analysis with trend mapping and benchmarking.
Competitive Intelligence
SWOT, Porter's Five Forces, and competitive positioning across market leaders.
Scenario Analysis
Three-scenario modelling (Base / Optimistic / Conservative) with CAGR decomposition.
Regulatory Review
Regulatory landscape, compliance requirements, and policy impact analysis by region.
Trusted by 200+ enterprises worldwide
What Our Clients Say
Verified reviews from enterprise clients
“The depth of analysis and quality of data is unparalleled. This report directly informed our $50M market expansion strategy and helped us prioritise the right geographies.”
Sarah Chen
VP Strategy, Fortune 500 Manufacturer
“Exceptional research quality. The competitive landscape section alone saved our team months of primary research effort and gave us a clear view of the opportunity.”
Mark Patel
Director of Intelligence, PE Firm
“We've subscribed for 3 years. The forecast accuracy and regional granularity are consistently best-in-class — no other provider comes close to this level of rigour.”
Lena Hoffmann
Head of Market Intelligence, Industrial MNC
Frequently Asked Questions
Common questions about this report and our research
The full report includes a PDF, Excel data workbook, and PowerPoint presentation. Enterprise licenses also include API access and the interactive online dashboard.
Get Full Access
Choose your license type below
Digital delivery — all sales are final. See our Refund Policy and Terms & Conditions.
What's Included